Lymphoma Rounds: Chicago
The Crowne Plaza Chicago West Loop (click here for directions)
25 South Halsted Street
Chicago, IL 60661
Wednesday, March 6, 2019
6:30 PM – 9:00 PM
PROGRAM AGENDA – TBA
This program is free for healthcare professionals; however, pre-registration is required. Food and refreshments will be provided for all registered participants.
Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please contact Piper Harmon, firstname.lastname@example.org. Exhibit opportunities are also available, however, space is limited.
Companies that have secured a national exhibit sponsorship for Lymphoma Rounds must still rsvp by emailing Piper Harmon (email@example.com) at least one week before the program to confirm their attendance. Otherwise, an exhibit table will not be guaranteed.
ABOUT THE PROGRAM
The Lymphoma Research Foundation’s Chicago Lymphoma Rounds program provides a forum for healthcare professionals to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Participants will network, share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the Chicago area.
At the conclusion of this educational activity, the participant should be better able to:
- Summarize the latest developments in lymphoma diagnosis, treatment and management.
- Apply best practices for treating lymphoma patients.
- Inform patients about potential clinical trial opportunities.
- Establish a network of health care professionals who work with lymphoma patients.
Lymphoma Research Foundation and the University of Nebraska Medical Center, Center for Continuing Education
This activity is supported by educational grants from:
AbbVie Inc., Celgene Corporation, Genentech, Novartis, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Seattle Genetics, Inc., TG Therapeutics, Inc. and Verastem Oncology